Christopher Medlock James’ Partner Fund Bullish on $GILD $WYN

Christopher Medlock James is the Managing Partner of Partner Fund Management. James cofounded the San Francisco-based fund in 2004 after spending six years in money management. Christopher James co-founded Andor Capital previously. Partner Fund Management has almost $5 billion in assets under management in four different fund. Partner Fund Management’s flagship fund returned 31% in 2007, lost 6% in 2008, gained 21% in 2009, and 4% in 2010. Christopher Medlock James is also the co-owner of the Medlock Ames winery at Bell Mountain. Partner Fund Management had $1.5 billion in its 13F fund at the end of December. That value is spread across 44 positions. This is fair difference from where the fund stood at the end of the third quarter, when it had 57 positions with a collective value of just under $1.10 billion – and those differences are even more pronounced in the actual holdings.

Gilead Sciences, Inc. (NASDAQ:GILD)

At the end of the third quarter, Partner Fund Management’s largest position was in Lowes (LOW). The fund held 5.36 million shares in the company, with a total value of $103.68 million. As of the end of the fourth quarter, Partner Fund Management’s position in Lowes was roughly half that, with just 2.59 million shares, at a value of $65.66 million. Instead, at the end of the fourth quarter, a new position in Gilead Sciences (GILD) was Partner Fund Management’s largest position. The fund had 3.89 million shares, or approximately $159.10 million, in the company.

Gilead, which is a top pick for both Samuel Isaly’s Orbimed Advisors and Dan Loeb’s Third Point, is a company that we can definitely get behind. When the markets opened on February 15, the company was trading at $54.88 with a one-year target estimate of $58.83 (range $45 to $67). Gilead was also priced low, at just 12.40 times its future earnings, and has low volatility – its beta is just 0.55. Over the last 52 weeks, the company has had great success, returning 38.51% versus the S&P 500’s 1.0%. Bristol-Myers Squibb (BMY), Gilead’s closest competitor has roughly the same upside – it opened at $31.84 on a one-year target estimate of $33.61 and pays a $1.36 dividend (4.30%) – but it isn’t priced nearly as well. Bristol-Myers Squibb has a high forward P/E of 16.43, and it hasn’t returned nearly as much. The company brought in just 24.32% over the last 52 weeks. It’s not that its numbers are bad necessarily; it’s just that they aren’t as good as Gilead’s.

Partner Fund Management’s second largest position at the end of the fourth quarter was in Wyndham Worldwide (WYN). The fund owned just under 3.10 million shares, or $117.24 million, in the company at the end of December. Wyndham opened trading on February 15 at $43.97 a share with a mean one-year target estimate of $48.23 (range $45 to $50). In addition to the upside, Wyndham pays a 60 cents dividend (1.40% yield). It is also priced low, trading at just 12.76 times its forward earnings, and has strong performance. Wyndham returned 36.59% over the last 52 weeks.

Compared to Marriott International (MAR), one of its top competitors, Wyndham shines even brighter. Marriott opened trading on February 15 at $35.22 a share with a one-year target estimate of $37.67. The company pays a dividend of 40 cents (1.10%) but it isn’t enough to make up for the lack of upside. Even more tellingly, Marriott is priced at 21.98 times its forward earnings and has lost over 15% in the last 52 weeks.

Christopher Medlock James’ Partner Fund was also bullish about Rockwell Automation (ROK), Caterpillar (CAT), American Tower (AMT), and Apple (AAPL) at the end of the fourth quarter. Apple is a no-brainer for a large proportion of equity hedge fund managers. When Apple was trading around $370 in early December, we had investors asking us whether Apple will close above $400 at the end of 2011. “There are no guarantees in the stock market, especially we can’t predict what will happen in the very short-term. However, Apple is trading at an extremely low forward PE ratio and the stock should perform well over the next few years,” we responded. Just in 2 short months Apple went up 40% but Apple’s story remains intact. Its earnings surprised to the upside and the stock is still cheap in relation to its forward PE multiples.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!